Bill Detail
S. 2531
Congress: 119
Title
Uterine Fibroid Intervention and Gynecological Health Treatment Act of 2025
Summary
Uterine Fibroid Intervention and Gynecological Health Treatment Act of 2025 This bill authorizes grants to support early detection of and intervention for uterine fibroids. Uterine fibroids are tumors in the wall of the uterus that are usually benign but can cause painful and heavy menstrual bleeding and other symptoms. The bill requires the Department of Health and Human Services (HHS) to (1) conduct or support research on increasing early detection of and medical intervention for uterine fibroids, and (2) formulate strategies to increase early detection based on such research. Also, the bill authorizes HHS to provide grants to states to increase early detection of and intervention for uterine fibroids (e.g., screenings) and to carry out public awareness campaigns. Additionally, the bill authorizes HHS to provide grants to states for research relating to (1) disparities in pain management in uterine fibroid surgical treatment; or (2) uterine health conditions, as determined appropriate by HHS. HHS must report to Congress every two years on the activities funded by grants under the bill, including findings from the research conducted by states.
Sponsor
Sen. Angela Alsobrooks [D-MD]
Status
Committee on Health, Education, Labor, and Pensions. Hearings held.
Status as of Sep 30, 3:48 PM · synced 1d ago
Introduced
2025-07-30
Data source mode: congress-gov
Bill Engagement
Uterine Fibroid Intervention and Gynecological Health Treatment Act of 2025 This bill authorizes grants to support early detection of and intervention for uterine fibroids.
Lobbyists on the case
- American Apparel & Footwear Association2 filings · 7 lobs
- Audrey Clark2026 Q1
- Jennifer Hanks2026 Q1
Prepared intelligence brief
Connect the event to the surrounding activity.
Unlock every organization and lobbyist filing on this bill, the complete event and issue map, private team positions, and recurring movement alerts across the portfolio.